Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating

Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU markets. I like to delve into clinical catalysts or play earnings on new drug launches. I do not provide personal investment advice. All content that I provide, including but not limited to opinions, analyses, commentaries, forecasts, stock picks, and investment strategies, is for informational and educational purposes only and should not be interpre ...